Tvardi Therapeutics (TVRD) Financials

Tvardi Therapeutics (NASDAQ: TVRD) continues to look like a cash-rich but still deeply loss-making clinical-stage biotech. The latest quarter shows a company with meaningful liquidity, no debt, and enough cash plus short-term investments to fund operations for the near term — but also one that is still burning through capital with no revenue on the income statement.

What stands out most: TVRD reported no revenue in Q1 2026, a net loss of $6.8 million, and negative operating cash flow of $5.9 million. Offsetting that, the balance sheet remains relatively strong for a development-stage biotech, with $19.9 million in cash and $5.1 million in short-term investments, or about $25.0 million of liquid assets.

• Cash position remains solid: Tvardi ended Q1 2026 with $19.9 million in cash and equivalents plus $5.1 million in short-term investments.
• No long-term debt: The company reported $0 of long-term debt, which reduces balance sheet risk.
• Quarterly net loss improved slightly year over year: Q1 2026 net loss of $6.8 million was narrower than $7.3 million in Q4 2025.
• Operating cash burn moderated sequentially: Cash used in operations improved to $5.9 million in Q1 2026 from $5.7 million in Q4 2025, while remaining well below several earlier periods in 2024.
• Interest and investment income helped offset losses: Tvardi generated $247,000 in interest and investment income in Q1 2026.
• Liquidity is tied to investments: A meaningful portion of assets sits in short-term investments, so near-term funding depends on ongoing portfolio liquidity and management of burn rate.
• Equity base is still positive: Total common equity was $14.5 million at the end of Q1 2026.
• Quarterly spending remained focused on R&D: Research and development expense was $4.9 million, indicating continued clinical or preclinical investment.
• Share count is relatively stable in the recent quarters: Basic weighted average shares were 9.38 million in Q1 2026 versus 7.42 million in Q4 2025, but the latest balance sheet does not show a dramatic new dilution event in the quarter.
• No revenue yet: The company reported $0 in revenue in Q1 2026, so it remains dependent on financing and/or future clinical success.
• Still burning cash: Operating cash flow was negative $5.9 million in Q1 2026, and financing cash flow was zero, which means the business is still consuming existing resources.
• Accumulated deficit remains large: Retained earnings were negative $117.3 million, reflecting years of losses.
• Current liabilities are sizeable relative to cash: Tvardi had $11.3 million in total liabilities, including $6.5 million of accrued expenses and $4.6 million of accounts payable.
• Historical volatility is high: The company’s quarterly results have been highly uneven over the last several years, including periods of large losses, asset write-downs/other expense swings, and major changes in share count.

Longer-term trend: Over the last four years, Tvardi’s financial profile has shifted from a larger balance sheet with significant cash and investments in 2023-2024 to a much smaller cash position by early 2026. At the same time, the company has remained structurally unprofitable and reliant on non-operating sources or financing-related activities to support operations. That’s typical for a biotech, but it means the investment case depends heavily on clinical progress and future capital access.

Bottom line: Tvardi Therapeutics enters 2026 with enough liquidity to keep operating for now, but the core story is still about cash runway and pipeline execution, not earnings. Investors should watch the pace of cash burn, any new financing, and whether operating expenses begin to translate into clinical or strategic progress.